Tarnow

• A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc … Unknown
  2022-502779-40-99 5 Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
• A double-dummy, double-blind, randomized, active controlled, two-way cross-over study with 12-week treatment duration per period, to evaluat … Pending
  2022-502365-26-00 5 Asthma
• Randomised efficacy and safety clinical trial of PQ Birch in subjects with seasonal allergic rhinitis and/or rhinoconjunctivitis induced by … Pending
  2023-507427-28-00 5 seasonal allergic rhinitis and/or rhinoconjunctivitis
• A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Eblasakimab in Male or Female Moder … Pending
  2023-508329-28-00 4 Atopic Dermatitis
• A Study to Learn About the Study Medicine Called PF-07275315 in Adults with Moderate-To-Severe Long-Term Breathing Difficulty, Known by the … Pending
  2024-518587-12-00 4 MODERATE-TO-SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
• BETRI-Prospective: Asthma control in Single Inhaler ICS/LABA/LAMA (87/5/9 pMDI [BDP/FF/GB - 100/6/12.5 µg]) vs Single Inhaler ICS/LABA (200/ … Pending
  2025-524289-56-00 6 Asthma
• A Phase II study to investigate lung function with 2 different doses of inhaled glycopyrronium taken with BFF compared to BFF in participant … Pending
  2025-524914-26-00 4 Asthma
• A Study of KT-621 Administered Orally to Adult Participants with Moderate to Severe Eosinophilic Asthma Recruiting
  2025-523180-38-00 4 2026-05-12 Uncontrolled Moderate to Severe Eosinophilic Asthma
• An open-label extension (OLE) trial to evaluate long-term safety and tolerability of pelacarsen (TQJ230) Recruiting
  2024-519870-38-00 5 2026-05-11 Atherosclerotic cardiovascular disease (ASCVD)
• Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants with Chronic Spontaneous Urticaria Recruiting
  2025-522878-36-00 5 2026-04-20 Chronic Spontaneous Urticaria
• A phase 3 multi-center trial to evaluate the efficacy and safety of tralokinumab in combination with topical corticosteroids in children (ag … Recruiting
  2023-503630-44-00 10 2024-11-20 Treatment of moderate-to-severe Atopic dermatitis
• A randomised, double-blind, double-dummy, multicentre, phase III, non inferiority trial of an oral mesalazine formulation in patients with a … Recruiting
  2023-509606-30-00 5 2024-07-24 Ulcerative colitis
• Long-Term Safety and Efficacy evaluation of amlitelimab in participants of previous amlitelimab moderate to severe atopic dermatitis clinica … Recruiting
  2023-506548-18-00 10 2022-11-10 Dermatitis atopic
• A study to demonstrate the efficacy of PMBL (Ismigen) in the reduction of respiratory infections in children aged 3 to 12 years. Recruiting
  2025-524212-11-00 6 2026-05-18 Respiratory Tract Infections
• A clinical study to evaluate the effects of RO7795068 in participants with obesity or overweight without type 2 diabetes. Recruiting
  2025-523104-71-00 5 2026-05-08 Obesity or Overweight Without Type 2 Diabetes
• EFFICACY AND SAFETY OF MET097 ONCE WEEKLY IN PEOPLE WITH OVERWEIGHT OR OBESITY AND TYPE 2 DIABETES (VESPER-5) Recruiting
  2025-523975-48-00 5 2026-05-08 Obesity
• COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME Recruiting
  2025-523937-25-00 5 2026-05-06 Diabetic Macular Edema (DME)
• A Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Finding Study of CX11 Tablets in Patients with Type 2 Diabetes Mellitus Recruiting
  2025-524514-28-00 4 2026-05-06 Type 2 Diabetes Mellitus
• HF-POLARIS: A research study to look at how well NNC0487-0111 works compared to placebo in people with heart failure and obesity Recruiting
  2025-523717-29-00 5 2026-04-28 HFpEF or HFmrEF and obesity
• A Phase 2 Study of Lesigercept (YH35324) in Adult Patients with Chronic Spontaneous Urticaria (CLEAR) Recruiting
  2025-524006-14-00 4 2026-04-20 Chronic Spontaneous Urticaria
• Therapeutic equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in subjects with mild to moderate asthma (TRECONY) Recruiting
  2025-521456-35-00 4 2026-04-13 Mild to moderate asthma
• Phase 3 Study of Barzolvolimab in Participants with Cold Induced Urticaria and Symptomatic Dermographism Recruiting
  2025-522583-32-00 5 2026-04-13 Cold-Induced Urticaria and Symptomatic Dermographism
• A study to learn if galvokimig is safe and works in adults with moderate to severe atopic dermatitis Recruiting
  2025-522578-35-00 4 2026-03-30 Atopic Dermatitis
• A Study to Learn About the Study Medicine Called Ritlecitinib in People With Hives Without a Known Cause Recruiting
  2025-522642-44-00 4 2026-03-18 CHRONIC SPONTANEOUS URTICARIA

Showing 1–24 of 108 trials